Clazosentan: Prevention of cerebral vasospasm and the potential to overcome infarction

Acta Neurochirurgica, Supplementum

Volumn 110, Issue , 2011, Pages 147-150

  Beck, Juergen ^a   Raabe, Andreas ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Aneurysmal subarachnoid hemorrhage; Cerebral vasospasm; Clazosentan; CONSCIOUS 1 study

Indexed keywords

CLAZOSENTAN; NIMODIPINE; PLACEBO;

ADULT; AGED; ANEMIA; BLOOD PRESSURE; BRAIN ANGIOGRAPHY; BRAIN INFARCTION; BRAIN VASOSPASM; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED STUDY; DIGITAL SUBTRACTION ANGIOGRAPHY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GLASGOW OUTCOME SCALE; HUMAN; LONG TERM CARE; LUNG DISEASE; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; SUBARACHNOID HEMORRHAGE;

EID: 85052608970     PISSN: 00651419     EISSN: 00016268     Source Type: Book Series    
DOI: 10.1007/978-3-7091-0356-2_26     Document Type: Conference Paper

References (10)

1. Bederson JB, Connolly ES, Jr, Batjer HH, Dacey RG, Dion JE, Diringer MN, et al., American Heart Association. Guidelines for the management of aneurysmal subarachnoid hemorrhage: A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 2009;40: 994-1025
2. Crowley RW, Medel R, Kassell NF, Dumont AS. New insights into the causes and therapy of cerebral vasospasm following subarachnoid hemorrhage. Drug Discov Today. 2008;13:254-260
3. de Rooij NK, Linn FHH, van der Plas JA, Algra A, Rinkel GJE. Incidence of subarachnoid haemorrhage: A systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry. 2007;78:1365-1372
4. Keyrouz SG, Diringer MN. Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage. Critical Care. 2007;11:220
5. Macdonald RL, Pluta RM, Zhang JH. Cerebral vasospasm after subarachnoid hemorrhage: The emerging revolution. Nat Clin Pract Neurol. 2007;3:256-263
6. Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, et al.; CONSCIOUS-1 Investigators. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): Randomized, double-Blind, placebo-controlled phase 2 dose-finding trial. Stroke 2008;39:3015-3021
7. Pluta RM, Hansen-Schwartz J, Dreier J, Vajkoczy P, Macdonald RL, Nishizawa S, et al. Cerebral vasospasm following subarachnoid hemorrhage: Time for a new world of thought. Neurol Res. 2009;31:151-158
8. Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: Results of a randomized, double-Blind, placebo-controlled, multicenter phase IIa study. J Neurosurg. 2005;103:9-17
9. van Giersbergen PL, Gunawardena KA, Dingemanse J. Influence of ethnic origin and sex on the pharmacokinetics of clazosentan. J Clin Pharmacol. 2007;47:1374-1380
10. Weidauer S, Lanfermann H, Raabe A, Zanella F, Seifert V, Beck J. Impairment of cerebral perfusion and infarct patterns attributable to vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 2007;38:1831-1836